| Helicobacter Pylori |
1 |
1 |
| Clinical Guidelines |
0 |
0.75 |
| Proton Pump Inhibitor |
0 |
0.66 |
| Noncolorectal Gastrointestinal Cancer |
0 |
0.48 |
| Antibiotics |
0 |
0.41 |
| Non-Hodgkin Lymphoma (NHL) |
0 |
0.31 |
| Complementary and Alternative Medicine |
0 |
0.27 |
| Microbiome |
0 |
0.27 |
| Allergy |
0 |
0.26 |
| Biologic Therapy |
0 |
0.23 |
| Peptic Ulcer Disease |
0 |
0.23 |
| Thrombocytopenia |
0 |
0.23 |
| Genomic Medicine |
0 |
0.21 |
| Drug Allergy |
0 |
0.19 |
| Gastritis |
0 |
0.14 |
| Gastroesophageal Reflux Disease |
0 |
0.14 |
| Pain Management |
0 |
0.14 |
| Patient Safety |
0 |
0.14 |
| Adenocarcinoma |
0 |
0.13 |
| Probiotics |
0 |
0.13 |
| Virginia |
0 |
0.13 |
| Marginal Zone B-Cell Lymphoma |
0 |
0.11 |
| B-Cell Lymphoma |
0 |
0.09 |
| Gastric Cancer |
0 |
0.09 |
| Idiopathic Thrombocytopenic Purpura |
0 |
0.09 |
| Adverse Effects |
0 |
0.07 |
| Antibiotic Resistance |
0 |
0.07 |
| Antigens |
0 |
0.07 |
| Aspirin |
0 |
0.07 |
| Biopsy |
0 |
0.07 |
| Cancer |
0 |
0.07 |
| DNA Sequencing |
0 |
0.07 |
| Dyspepsia |
0 |
0.07 |
| Histamine |
0 |
0.07 |
| Lymphoma |
0 |
0.07 |
| Nonsteroidal Anti-Inflammatory Agents |
0 |
0.07 |
| Receptors |
0 |
0.07 |
| Thrombocytopenic Purpura |
0 |
0.07 |